Exelixis at #ESMO24 (Credit: Reynald Castañeda for Endpoints News)
September 16, 2024 08:45 AM EDTUpdated 09:00 AM
R&D

Ex­elix­is’ drug staves off neu­roen­docrine tu­mor pro­gres­sion in broad swath of pa­tients

Lei Lei Wu

News Reporter

BARCELONA — A new treat­ment op­tion for a wide range of pa­tients di­ag­nosed with neu­roen­docrine tu­mors could be ap­proved in April, as fi­nal re­sults of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times